Lv4
480 积分 2021-12-06 加入
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
16小时前
待确认
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
8天前
已完结
Exploring the mechanism of Huanglian ointment in alleviating wound healing after anal fistula surgery through metabolomics and proteomics
17天前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
26天前
已完结
Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts
26天前
已完结
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
2个月前
已完结
Second-line treatment for ovarian cancer
2个月前
已完结
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
2个月前
已完结
Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer
3个月前
已完结
Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors
3个月前
已关闭
皖公网安备34019202002308
